argenx to Present at Annual J.P. Morgan Healthcare Event
On January 6, 2025, argenx, a global leader in immunology, announced that their Chief Executive Officer, Tim Van Hauwermeiren, will be presenting at the prestigious 43rd Annual J.P. Morgan Healthcare Conference. This event, known for gathering key players in the healthcare industry, will take place on January 13, 2025, at 9:45 a.m. PT.
Significance of the J.P. Morgan Healthcare Conference
This conference is pivotal for investors and industry professionals as it highlights the most innovative companies in healthcare and biopharmaceuticals. Tim Van Hauwermeiren’s participation is particularly significant as argenx continues to make strides in treating severe autoimmune diseases, a crucial area of focus in modern medicine.
What to Expect from the Presentation
During his presentation, Van Hauwermeiren is expected to discuss the advancements and innovative treatments being developed by argenx. There will likely be insights into the company’s commitment to improving patient lives through carefully crafted antibody-based therapies.
Live Webcast Access
For those unable to attend in person, a live webcast of the presentation will be available. Interested parties can access the webcast through the Investors section of argenx's website. Following the event, a replay will be hosted on the same platform for approximately 30 days, ensuring that all stakeholders have the opportunity to access the information shared.
About argenx
argenx is recognized for its dedication to addressing the unmet medical needs of patients suffering from serious autoimmune conditions. The company has established partnerships with leading academic institutions through its Immunology Innovation Program (IIP). This collaboration aims to drive forward promising immunological discoveries into therapies that offer real solutions.
Key Focus Areas and Innovations
One of the standout achievements of argenx is the successful development and commercialization of the first approved neonatal Fc receptor (FcRn) blocker. This innovative treatment is available globally, including in the U.S., Japan, and several European countries. argenx is also actively conducting evaluations of efgartigimod across multiple severe autoimmune diseases, with additional projects in the pipeline.
Engagement and Information Resources
As part of its ongoing commitment to transparency and communication, argenx actively engages with investors and the broader community. They encourage people to stay informed about their advancements and success stories through various online platforms such as their official website and social media channels. Connecting with argenx on social media platforms will provide insights into their latest developments and milestones.
Company Contact Information
For any further inquiries related to media or investment specifics regarding argenx, there are dedicated contacts available. For media-related questions, Ben Petok is the point of contact at bpetok@argenx.com. For inquiries related to investors, Alexandra Roy (US) can be reached at aroyl@argenx.com, while Lynn Elton (EU) is available at lelton@argenx.com.
Frequently Asked Questions
1. What is the purpose of the J.P. Morgan Healthcare Conference?
The conference aims to showcase innovative healthcare companies and facilitate networking among industry leaders and investors.
2. Who is presenting at the conference from argenx?
Tim Van Hauwermeiren, the CEO of argenx, will be presenting at the event.
3. How can I access the presentation?
A live webcast of the presentation will be available on the argenx website, and a replay will be accessible for 30 days after the event.
4. What are the main focuses of argenx?
argenx primarily focuses on developing antibody-based therapies for severe autoimmune diseases with significant unmet medical needs.
5. Where can I find more information about argenx?
You can visit argenx's official website and follow them on their social media platforms for the latest updates and information.
